Abstract
Background: Peptide receptor radionuclide therapy (PRRT) is an emerging therapeutic option for the treatment of neuroendocrine tumors (NETs), and the number of publications in this field has been increasing in recent years. The aim of the present study was to present the research status and summarize the key topics through bibliometric analysis of published PRRT literature. Methods: A literature search for PRRT research from 2000 to 2019 was conducted using the Science Citation Index Expanded of Web of Science Core Collection (limited to SCIE) on August 4, 2020. The VOSviewer, R-bibliometrix, and CiteSpace software were used to conduct the bibliometric analysis. Results: From 2000 to 2019, a total of 681 publications (523 articles and 158 reviews) were retrieved. Annual publication outputs grew from three to 111 records. Germany had the largest number of publications, making the largest contribution to the field (n = 151, 22.17%). Active cooperation between countries/regions was observed. Kwekkeboom from the Erasmus Medical Center is perhaps a key researcher in the field of PRRT. The European Journal of Nuclear Medicine and Molecular Imaging and Journal of Nuclear Medicine ranked first for productive (n = 84, 12.33%) and co-cited (n = 3,438) journals, respectively. Important topics mainly included matters related to the efficacy of PRRT (e.g., 90Y-dotatoc and 177Lu-dotatate), the long-term adverse effects of PRRT (e.g., hematologic and renal toxicities), standardization of NETs and PRRT in practice, the development of medical imaging techniques, and the individual dose optimization of PRRT. Conclusion: Using bibliometric analysis, we gained deep insight into the global status and trends of studies investigating PRRT for the first time. The PRRT field is undergoing a period of rapid development, and our study provides a valuable reference for clinical researchers and practitioners.
Highlights
Peptide receptor radionuclide therapy (PRRT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabeled peptide (e.g., 90Y-dotatoc and 177Lu-dotatate), which is designed to target receptors overexpressed on tumors with high affinity and specificity (Zaknun et al, 2013)
We identified 681 publications associated with PRRT in the Web of Science Core Collection (WoSCC) from 2000 to 2019
Based on the top 12 co-cited references, we found that the knowledge base of PRRT research mainly involved the following aspects: efficacy of PRRT (e.g., 90Y-dotatoc and 177Lu-dotatate), adverse effects of PRRT, epidemiologic characteristics, and other therapies for neuroendocrine tumors (NETs) (e.g., GEP-NETs)
Summary
Peptide receptor radionuclide therapy (PRRT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabeled peptide (e.g., 90Y-dotatoc and 177Lu-dotatate), which is designed to target receptors overexpressed on tumors (e.g., somatostatin receptor subtype 2) with high affinity and specificity (Zaknun et al, 2013). As an emerging therapeutic option for NETs, the efficacy of PRRT with radiolabelled somatostatin analogs, such as 90Y-dotatoc and 177Lu-dotatate, is encouraging (Imhof et al, 2011; Pfeifer et al, 2011; Kam et al, 2012). Peptide receptor radionuclide therapy (PRRT) is an emerging therapeutic option for the treatment of neuroendocrine tumors (NETs), and the number of publications in this field has been increasing in recent years. The aim of the present study was to present the research status and summarize the key topics through bibliometric analysis of published PRRT literature
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
